Advertisement
ACET vs PCRX
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACET is a StrongBuy and PCRX is a Buy.
ACET's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for ACET turned positive on November 04, 2026. Looking at past instances where ACET's MACD turned positive, the stock continued to rise in 35 of 42 cases over the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Bearish Trend Analysis
The 50-day moving average for ACET moved below the 200-day moving average on October 21, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACET declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for ACET entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.238) is normal, around the industry mean (3.498). P/E Ratio (-0.293) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. ACET’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACET’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Momentum Indicator for PCRX turns positive, indicating new upward trend
PCRX saw its Momentum Indicator move above the 0 level on October 29, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 86 similar instances where the indicator turned positive. In 61 of the 86 cases, the stock moved higher in the following days. The odds of a move higher are at 71%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +0.17% 3-day Advance, the price is estimated to grow further. Considering data from situations where PCRX advanced for three days, in 214 of 304 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
The Aroon Indicator entered an Uptrend today. In 127 of 188 cases where PCRX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 68%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 22 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 57 cases where PCRX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 75%.
The Moving Average Convergence Divergence Histogram (MACD) for PCRX turned negative on October 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 41 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
PCRX broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. PCRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 84 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.161) is normal, around the industry mean (6.379). PCRX has a moderately high P/E Ratio (104.086) as compared to the industry average of (0.548). Projected Growth (PEG Ratio) (0.684) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (1.416) is also within normal values, averaging (183.387).
The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PCRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
ACET | PCRX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 51 | 40 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 47 Fair valued | 84 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 88 | |
PRICE GROWTH RATING 1..100 | 94 | 36 | |
P/E GROWTH RATING 1..100 | 8 | 5 | |
SEASONALITY SCORE 1..100 | n/a | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ACET's Valuation (47) in the Medical Distributors industry is somewhat better than the same rating for PCRX (84) in the Pharmaceuticals Other industry. This means that ACET’s stock grew somewhat faster than PCRX’s over the last 12 months.
ACET's Profit vs Risk Rating (100) in the Medical Distributors industry is in the same range as PCRX (100) in the Pharmaceuticals Other industry. This means that ACET’s stock grew similarly to PCRX’s over the last 12 months.
PCRX's SMR Rating (88) in the Pharmaceuticals Other industry is in the same range as ACET (98) in the Medical Distributors industry. This means that PCRX’s stock grew similarly to ACET’s over the last 12 months.
PCRX's Price Growth Rating (36) in the Pharmaceuticals Other industry is somewhat better than the same rating for ACET (94) in the Medical Distributors industry. This means that PCRX’s stock grew somewhat faster than ACET’s over the last 12 months.
PCRX's P/E Growth Rating (5) in the Pharmaceuticals Other industry is in the same range as ACET (8) in the Medical Distributors industry. This means that PCRX’s stock grew similarly to ACET’s over the last 12 months.
| ACET | PCRX | |
|---|---|---|
| RSI ODDS (%) | N/A | 6 days ago 88% |
| Stochastic ODDS (%) | N/A | 2 days ago 75% |
| Momentum ODDS (%) | N/A | 2 days ago 71% |
| MACD ODDS (%) | 2 days ago 83% | 2 days ago 85% |
| TrendWeek ODDS (%) | 2 days ago 88% | 2 days ago 71% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 71% |
| Advances ODDS (%) | N/A | 5 days ago 70% |
| Declines ODDS (%) | 2 days ago 89% | N/A |
| BollingerBands ODDS (%) | N/A | 2 days ago 76% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 68% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ACET’s FA Score shows that 1 FA rating(s) are green while PCRX’s FA Score has 1 green FA rating(s).
- ACET’s FA Score: 1 green, 4 red.
- PCRX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ACET’s TA Score shows that 1 TA indicator(s) are bullish while PCRX’s TA Score has 3 bullish TA indicator(s).
- ACET’s TA Score: 1 bullish, 3 bearish.
- PCRX’s TA Score: 3 bullish, 4 bearish.
Price Growth
ACET (@Biotechnology) experienced а -8.85% price change this week, while PCRX (@Pharmaceuticals: Generic) price change was +0.08% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -3.38%. For the same industry, the average monthly price growth was -5.88%, and the average quarterly price growth was -18.27%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.53%. For the same industry, the average monthly price growth was -5.74%, and the average quarterly price growth was +6.93%.
Reported Earning Dates
ACET is expected to report earnings on Mar 17, 2027.
PCRX is expected to report earnings on Mar 04, 2027.
Industries' Descriptions
@Biotechnology (-3.38% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Pharmaceuticals: Generic (-0.53% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
ACET and
Correlation & Price change
A.I.dvisor indicates that over the last year, ACET has been loosely correlated with VIR. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if ACET jumps, then VIR could also see price increases.
| Ticker / NAME | Correlation To ACET | 1D Price Change % | ||
|---|---|---|---|---|
| ACET | 100% | -5.12% | ||
| VIR - ACET | 42% Loosely correlated | -17.82% | ||
| OGI - ACET | 41% Loosely correlated | -0.65% | ||
| RXRX - ACET | 41% Loosely correlated | -4.35% | ||
| IMTX - ACET | 38% Loosely correlated | -1.99% | ||
| COYA - ACET | 38% Loosely correlated | -4.28% | ||
More | ||||
PCRX and
Correlation & Price change
A.I.dvisor tells us that PCRX and ELAN have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PCRX and ELAN's prices will move in lockstep.
| Ticker / NAME | Correlation To PCRX | 1D Price Change % | ||
|---|---|---|---|---|
| PCRX | 100% | N/A | ||
| ELAN - PCRX | 32% Poorly correlated | +1.06% | ||
| COLL - PCRX | 27% Poorly correlated | +1.48% | ||
| ACET - PCRX | 27% Poorly correlated | -5.12% | ||
| SNDL - PCRX | 26% Poorly correlated | -1.44% | ||
| SXTC - PCRX | 25% Poorly correlated | +9.89% | ||
More | ||||